278 related articles for article (PubMed ID: 23127340)
1. Breast cancer stem cells: a novel therapeutic target.
Gangopadhyay S; Nandy A; Hor P; Mukhopadhyay A
Clin Breast Cancer; 2013 Feb; 13(1):7-15. PubMed ID: 23127340
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.
Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM
Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207
[TBL] [Abstract][Full Text] [Related]
3. Implications of stemness-related signaling pathways in breast cancer response to therapy.
Angeloni V; Tiberio P; Appierto V; Daidone MG
Semin Cancer Biol; 2015 Apr; 31():43-51. PubMed ID: 25153354
[TBL] [Abstract][Full Text] [Related]
4. Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications.
Izrailit J; Reedijk M
Cancer Lett; 2012 Apr; 317(2):115-26. PubMed ID: 22123293
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
6. Novel Therapeutics Against Breast Cancer Stem Cells by Targeting Surface Markers and Signaling Pathways.
Das PK; Rakib MA; Khanam JA; Pillai S; Islam F
Curr Stem Cell Res Ther; 2019; 14(8):669-682. PubMed ID: 31808385
[TBL] [Abstract][Full Text] [Related]
7. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
Kai M; Onishi H; Souzaki M; Tanaka H; Kubo M; Tanaka M; Katano M
Cancer Sci; 2011 Dec; 102(12):2132-8. PubMed ID: 21838786
[TBL] [Abstract][Full Text] [Related]
8. Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Ito Y; Iwase T; Hatake K
Breast Cancer; 2012 Jul; 19(3):206-11. PubMed ID: 21526426
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer stem cells, EMT and therapeutic targets.
Kotiyal S; Bhattacharya S
Biochem Biophys Res Commun; 2014 Oct; 453(1):112-6. PubMed ID: 25261721
[TBL] [Abstract][Full Text] [Related]
10. Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications.
Alanazi IO; Khan Z
Asian Pac J Cancer Prev; 2016; 17(2):445-53. PubMed ID: 26925626
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
[TBL] [Abstract][Full Text] [Related]
12. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.
Grudzien P; Lo S; Albain KS; Robinson P; Rajan P; Strack PR; Golde TE; Miele L; Foreman KE
Anticancer Res; 2010 Oct; 30(10):3853-67. PubMed ID: 21036696
[TBL] [Abstract][Full Text] [Related]
14. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target.
Ginestier C; Monville F; Wicinski J; Cabaud O; Cervera N; Josselin E; Finetti P; Guille A; Larderet G; Viens P; Sebti S; Bertucci F; Birnbaum D; Charafe-Jauffret E
Stem Cells; 2012 Jul; 30(7):1327-37. PubMed ID: 22605458
[TBL] [Abstract][Full Text] [Related]
15. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer stem cells.
Kai K; Arima Y; Kamiya T; Saya H
Breast Cancer; 2010 Apr; 17(2):80-5. PubMed ID: 19806428
[TBL] [Abstract][Full Text] [Related]
17. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
20. Novel targeted agents for the treatment of advanced breast cancer.
de la Vega M; Díaz-Cantón E; Alvarez RH
Future Med Chem; 2012 May; 4(7):893-914. PubMed ID: 22571614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
